Search results for CD33 antibody

Biotin Anti-CD33 antibody [HIM3-4], Abcam, AB21892

The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.

Anti-CD33 antibody [BLR061G] - BSA free, Abcam, AB272082

ab272082 is the BSA-free version of ab264414 . REACH authorisation Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances. It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses. This product is sold under License from Bethyl Laboratories, Inc.

Anti-Human CD33 Antibody (SAA1404) (HB185307), abinScience, HB185307

Anti-Human CD33 Antibody (M195) (HB185207), abinScience, HB185207

Biotin Anti-CD33 antibody [EPR23052-5] (Detector), Abcam, AB322847

How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Myeloid Cell Surface Antigen CD33 (CD33) Antibody, Abbexa, abx132692

Myeloid Cell Surface Antigen CD33 (CD33) Antibody is a Rabbit Polyclonal antibody for the detection of Myeloid Cell Surface Antigen CD33 (CD33).

Myeloid Cell Surface Antigen CD33 (CD33) Antibody, Abbexa, abx028674

SIGLEC3 is a putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. It preferentially binds to alpha2, 6-linked sialic acid; the sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, SIGLEC3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase (s) via their SH2 domain (s) that block signal transduction through dephosphorylation of signaling molecules. This protein Induces apoptosis in acute myeloid leukemia (in vitro). It has been shown to interact with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. SIGLEC3 expresses in monocytic/myeloid lineage cells, and contains 2 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in downmodulation of cellular responses. The phosphorylated ITIM motif binds to the SH2 domain of PTPN6/SHP-1. Phosphorylation of Tyr-340 is involved in binding to PTPN6 and PTPN11. Phosphorylation of Tyr-358 is involved in binding to PTPN6. The gene for SIGLEC3 belongs to the immunoglobulin superfamily.

Anti-Human CD33 Antibody (SAA1404), PE (HB185327), abinScience, HB185327

PE/Cy5® Anti-CD33 antibody [WM53], Abcam, AB233448

This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy® and CyDye® are trademarks of Cytiva.

PE/Cy7® Anti-CD33 antibody [WM53], Abcam, AB239310

This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy® and CyDye® are trademarks of Cytiva.